{"database": "lobbying", "table": "lobbying_activities", "rows": [[2340935, "342d36e3-73ba-4521-b954-8b883435e4d5", "Q3", "RED+BLUE STRATEGIES", 400693064, "PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION (PCMA)", 2019, "third_quarter", "MMM", "H.R. 3 - The Lower Drug Costs Now Act of 2019 - Issues related to the role of PBMs in the new structure contemplated by the Act. \n\nHHS rules and regulations related  to the cost of prescription drugs, including, but not limited to,  limiting rebates in the Medicare and Medicaid prescription drug benefits. \n\nLegislative policies and reforms related to Medicare Part B and D specific to the price of prescription medications. \n\nC-THRU Act (S. 476) - Issues related to transparency in the PBM space and ensuring that tools to decrease the cost of prescription medications are maintained.", "HOUSE OF REPRESENTATIVES,SENATE", 60000, null, 0, 0, "2019-10-13T09:10:22.420000-04:00"]], "columns": ["id", "filing_uuid", "filing_type", "registrant_name", "registrant_id", "client_name", "filing_year", "filing_period", "issue_code", "specific_issues", "government_entities", "income_amount", "expense_amount", "is_no_activity", "is_termination", "received_date"], "primary_keys": ["id"], "primary_key_values": ["2340935"], "units": {}, "query_ms": 104.47833099169657, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}